In fact, the use of a blocking antibody to CTLA-4 (Ipilumimab) in metastatic melanoma patients demonstrated clinical efficacy [7] and was recently given approval by the FDA [9]. This evidence concerns the gene CTLA4 and metastatic melanoma.